Clinic and genetic predictors in response to erenumab

BACKGROUND AND PURPOSE: Erenumab (ERE) is the first anticalcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. A proportion of patients do not adequately respond to ERE. METHODS: Prospective multicenter study involving 110 migraine patients starting ERE 70 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Zecca, Chiara, Cargnin, Sarah, Schankin, Christoph, Giannantoni, Nadia Mariagrazia, Viana, Michele, Maraffi, Isabella, Riccitelli, Gianna Carla, Sihabdeen, Shairin, Terrazzino, Salvatore, Gobbi, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Headache
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306465/
https://www.ncbi.nlm.nih.gov/pubmed/34965002
http://dx.doi.org/10.1111/ene.15236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306465/
https://www.ncbi.nlm.nih.gov/pubmed/34965002
http://dx.doi.org/10.1111/ene.15236

Ejemplares similares